About US
Contact us
-
Celsion completes acquisition of EGENCelsion has completed the acquisition of EGEN, including its Phase Ib product candidate EGEN-001 and therapeutic platform technologies, TheraPlas, TheraSilence, and RAST. Under the terms of the agree2014/6/25
-
FDA accepts Cubist’s new drug application for ceftolozane/tazobactam with priority reviewCubist Pharmaceuticals' new drug application for its ceftolozane/tazobactam for treatment of complicated urinary tract infections and complicated intra-abdominal infections has been accepted by the US2014/6/25
-
CDC says 75 Atlanta-based staff possibly exposed to anthraxThe Centers for Disease Control and Prevention (CDC) has reported that 75 Atlanta-based staff may have been unintentionally exposed to live Bacillus anthracis, the cause of the anthrax disease, and ar2014/6/24
-
Takeda decides to terminate prostate cancer drug developmentJapan-based Takeda Pharmaceutical has announced the termination of orteronel (TAK-700) development for prostate cancer in Japan, the US and Europe. The company has voluntarily decided to end the deve2014/6/24
-
Janssen enters into licence agreement with Vertex for influenza A drugJanssen Pharmaceuticals and Vertex Pharmaceuticals have entered into an exclusive licence agreement to develop, manufacture and commercialise VX-787, an investigational medicine for treatment of influ2014/6/23
-
Pfizer in cancer immunotherapy collaboration with CellectisPfizer has announced a global strategic collaboration with France-based Cellectis for development of Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at selec2014/6/23
-
Pfizer submits biologics license application to FDA for meningitis B vaccinePfizer has submitted a biologics licence application to the US Food and Drug Administration (FDA) for approval of its vaccine candidate bivalent recombinant LP2086 (rLP2086) to help protect against in2014/6/20
-
FDA to vote on opioid-induced constipation pillsTheFDAhas announced it will vote this week on whether a class of drugs that treat opioid-induced constipation needs more clinical testing in light of a side effect: heart attack. The class of drugs in2014/6/20
-
DARA BioSciences receives FDA orphan drug designation for KRN5500DARA BioSciences has received orphan drug designation from the US Food and Drug Administration's (FDA) Office of Orphan Products Development for KRN5500, for treating multiple myeloma. Multiple myelo2014/6/19
-
Polymers for Solubility Enhancement Will Drive the Oral Solid Dosage Forms MarketPoor solubility has been a major challenge in the formulation development for oral solid dosage form (OSDF) pharmaceuticals, a preferred route for pharmaceutical consumption. Various methods have been2014/6/19